The complex pathology of diabetes, cardiovascular disease, and metabolic syndrome has driven an increased demand for quantitative measurement of biomarkers linked to these disease states. Obesity, which has reached epidemic proportions worldwide, is directly related to increased risk for diabetes, hypertension, atherosclerosis, and metabolic syndrome. Novel proteomic technologies have helped define key serum biomarkers produced in the gut and adipose tissue and altered in abundance in disease states.
MSD provides solutions to support and simplify your metabolic research needs. We offer singleplex and multiplex assays to measure biomarkers such as glucagon, insulin, and leptin.